Business Details
Innovative Drug Delivery Technology Solutions
Skinvisible Pharmaceuticals, Inc. is a leader in drug delivery innovation, specializing in advanced polymer technologies that enhance topical and transdermal formulations. Our patented Invisicare technology provides controlled release, superior skin adhesion, and enhanced therapeutic outcomes, offering non-invasive alternatives to traditional drug delivery methods. With strategic partnerships and a robust portfolio of licensed products, we deliver value through innovation in dermatology, obesity, metabolic disease, and rare skin disorders. Our team combines deep expertise in polymer science and pharmaceutical development to create solutions that improve patient compliance and treatment efficacy.Backed by a strong intellectual property portfolio, including multiple patents and trade secrets, we collaborate with global pharmaceutical leaders to bring groundbreaking therapies to market. Our commitment to research and development drives continuous advancement in drug delivery systems, ensuring safety, effectiveness, and patient-centric design. As an industry pioneer, we prioritize transparency, ethical practices, and long-term partnerships to maximize therapeutic impact and shareholder value.
Services
Drug Delivery Development
Patent Licensing
Dermatology Treatments
Obesity Treatment Solutions
Research & Development
Highlights and features
- We leverage patented Invisicare technology for advanced transdermal drug delivery.
- Our team has decades of experience in polymer science and pharmaceutical development.
- We offer non-invasive alternatives to injections with proven clinical efficacy.
- Our collaborations with global pharmaceutical leaders ensure rigorous validation and scalability.
- Our solutions prioritize patient compliance and safety through controlled release mechanisms.
Services
Invisicare Polymer Technology
Invisicare is a patented polymer platform enhancing transdermal absorption of active ingredients without needles or patches. This technology achieves controlled release and superior skin adhesion, improving therapeutic outcomes for conditions like obesity and rare skin diseases. By enabling non-invasive delivery, Invisicare increases patient compliance and reduces side effects associated with oral or injectable treatments.
Dermatology Formulations
Our dermatology expertise develops topical treatments for rare and common skin diseases using Invisicare's controlled-release properties. These formulations maximize active ingredient penetration while maintaining skin safety and respiration. Current applications include Netherton Syndrome and acne treatments, with proven clinical efficacy through licensee partnerships like Quoin Pharmaceuticals.
Obesity Treatment Development
We advance transdermal obesity therapies using cannabinoids and GLP-1 agonists, offering needle-free alternatives with enhanced bioavailability. Our technology achieves up to 99.6% transdermal penetration of active agents, improving adherence compared to injections. Partnering with Ovation Science expands applications for metabolic health and diabetes management.
Patent Licensing
Skinvisible Pharmaceuticals licenses Invisicare for pharmaceutical applications, providing exclusivity and proprietary formulation support. Licensees gain access to patented delivery methods, regulatory expertise, and formulation customization for diverse therapeutic areas. This model accelerates market entry while maintaining rigorous safety and efficacy standards.
Research Partnerships
We collaborate with pharmaceutical companies to optimize drug delivery systems through joint research initiatives. These partnerships focus on expanding Invisicare's applications in unmet medical needs, from rare diseases to metabolic disorders, while ensuring compliance with FDA and international regulatory frameworks.
People
Terry Howlett
President & Chief Executive Officer
Terry Howlett leads Skinvisible Pharmaceuticals's strategic growth, leveraging extensive pharmaceutical industry experience in business development and executive leadership to expand the company's global licensing footprint.
Doreen McMorran
Vice President, Business Development
Doreen McMorran drives partner acquisition and licensing agreements, utilizing expertise in pharmaceutical business development to identify therapeutic areas where Invisicare can create clinical and commercial value.
James A. Roszell
Head, Research & Development
James Roszell oversees formulation science and technological innovation, applying his drug development expertise to strengthen Skinvisible Pharmaceuticals's intellectual property portfolio and delivery system performance across therapeutic applications.
Questions
What is Skinvisible Pharmaceuticals's Invisicare technology?
Invisicare is a patented polymer system enabling controlled transdermal drug delivery without needles or patches, enhancing efficacy and patient compliance.
How does Skinvisible Pharmaceuticals address obesity treatment?
Invisicare delivers GLP-1 agonists and other agents transdermally for obesity management, offering a non-invasive alternative to injections.
Does Skinvisible Pharmaceuticals develop products directly?
We focus on licensing our technology to pharmaceutical partners, who advance formulations for clinical trials and commercialization.
What rare diseases does Skinvisible Pharmaceuticals target?
Invisicare supports treatments for rare skin diseases like Netherton Syndrome through partnerships like Quoin Pharmaceuticals' QRX003 program.
How does Skinvisible Pharmaceuticals ensure product safety?
Invisicare uses GRAS-listed components and undergoes rigorous testing, including FDA-registered laboratory validation for delivery efficacy and skin interaction.
